Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity.

It is widely recognized that either predicting or determining the absorption, distribution, metabolism, excretion and toxicity (ADME/Tox) properties of molecules helps to prevent the failure of some compounds before they reach the clinic. Consequently, there has been considerable research into developing better in silico, in vitro and in vivo methods and models. Toxicogenomics, proteomics, metabonomics and pharmacogenomics represent the latest experimental approaches that can be combined with high-throughput molecular screening of targets to provide a view of the complete biological system that is modulated by a compound. The functional interpretation and relevance of these complex multidimensional data to the phenotype observed in humans is the focus of current research in toxicology. Multiple content databases, data mining and predictive modeling algorithms, visualization tools, and high-throughput data-analysis solutions are being integrated to form systems-ADME/Tox. In this review, we focus on the most recent advances and applications in this area.

[1]  D. Greenblatt,et al.  Interactions of tamoxifen, N‐desmethyltamoxifen and 4‐hydroxytamoxifen with P‐glycoprotein and CYP3A , 2004, Biopharmaceutics & drug disposition.

[2]  I. Wilson,et al.  Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism , 2003, Nature Reviews Drug Discovery.

[3]  J. Klein,et al.  Overview of proteomics. , 2004, Contributions to nephrology.

[4]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[5]  L. Hood,et al.  The digital code of DNA , 2003, Nature.

[6]  S. Ekins.  In silico approaches to predicting drug metabolism, toxicology and beyond. , 2003, Biochemical Society transactions.

[7]  Sean Ekins,et al.  Development of Computational Models for Enzymes, Transporters, Channels, and Receptors Relevant to ADME/Tox , 2004 .

[8]  Russ B. Altman,et al.  Ontology Development for a Pharmacogenetics Knowledge Base , 2001, Pacific Symposium on Biocomputing.

[9]  B. Stockwell.  The biological magic behind the bullets , 2004, Nature Biotechnology.

[10]  Dominic P. Williams,et al.  Idiosyncratic toxicity: the role of toxicophores and bioactivation. , 2003, Drug discovery today.

[11]  R. Tennant,et al.  Systems toxicology and the Chemical Effects in Biological Systems (CEBS) knowledge base. , 2002 .

[12]  Bruno Boulanger,et al.  Towards a new age of virtual ADME/TOX and multidimensional drug discovery , 2002, J. Comput. Aided Mol. Des..

[13]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Mortishire-Smith,et al.  A proteomic investigation of drug-induced steatosis in rat liver. , 2004, Chemical research in toxicology.

[15]  John Quackenbush,et al.  The quest for the mechanisms of life , 2003, Biotechnology and bioengineering.

[16]  L. Mirny,et al.  Protein complexes and functional modules in molecular networks , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Thompson,et al.  Application of proteomic technologies in the drug development process. , 2003, Toxicology letters.

[18]  K. Nakata,et al.  A Nuclear Receptor Database that Maps Pathways to Diseases , 2002 .

[19]  Benno Schwikowski,et al.  Discovering regulatory and signalling circuits in molecular interaction networks , 2002, ISMB.

[20]  Matej Oresic,et al.  Integrative biological analysis of the APOE*3-leiden transgenic mouse. , 2004, Omics : a journal of integrative biology.

[21]  J. Lehár,et al.  Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Ulrich.  The toxicogenomics of nuclear receptor agonists. , 2003, Current opinion in chemical biology.

[23]  P. Lord.  Progress in applying genomics in drug development. , 2003, Toxicology letters.

[24]  Stephen H. Friend,et al.  Toxicogenomics and drug discovery: will new technologies help us produce better drugs? , 2002, Nature Reviews Drug Discovery.

[25]  Grant W. Brown,et al.  Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways , 2004, Nature Biotechnology.

[26]  Michael D Waters,et al.  Database development in toxicogenomics: issues and efforts. , 2004, Environmental health perspectives.

[27]  James Delproposto,et al.  High-throughput phenotypic profiling of gene-environment interactions by quantitative growth curve analysis in Saccharomyces cerevisiae. , 2004, Analytical biochemistry.

[28]  Licia Iacoviello,et al.  Trends in pharmacogenomics of drugs acting on hypertension. , 2004, Pharmacological research.

[29]  Weida Tong,et al.  ArrayTrack--supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research. , 2003, Environmental health perspectives.

[30]  O. Fiehn,et al.  Can we discover novel pathways using metabolomic analysis? , 2002, Current opinion in biotechnology.

[31]  Nigel Greene,et al.  Computer systems for the prediction of toxicity: an update. , 2002, Advanced drug delivery reviews.

[32]  K. Igarashi,et al.  Mechanisms of benzene-induced hematotoxicity and leukemogenicity: cDNA microarray analyses using mouse bone marrow tissue. , 2003, Environmental health perspectives.

[33]  N. Anderson,et al.  Proteome and proteomics: New technologies, new concepts, and new words , 1998, Electrophoresis.

[34]  H. Langen,et al.  Mass spectrometry: A tool for the identification of proteins separated by gels , 2000, Electrophoresis.

[35]  Donna L Mendrick,et al.  Toxicogenomics: a new revolution in drug safety. , 2002, Drug discovery today.

[36]  L. Lesko,et al.  Microarray data—the US FDA, industry and academia , 2003, Nature Biotechnology.

[37]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[38]  H. Mewes,et al.  Functional modules by relating protein interaction networks and gene expression. , 2003, Nucleic acids research.

[39]  S. Kennedy.  The role of proteomics in toxicology: identification of biomarkers of toxicity by protein expression analysis , 2002, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[40]  Markus J. Herrgård,et al.  Integrating high-throughput and computational data elucidates bacterial networks , 2004, Nature.

[41]  David A. Flockhart,et al.  Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[42]  Mark W. Craven,et al.  Identification of toxicologically predictive gene sets using cDNA microarrays. , 2001, Molecular pharmacology.

[43]  Scott Boyer,et al.  New methods in predictive metabolism , 2002, J. Comput. Aided Mol. Des..

[44]  Ben van Ommen,et al.  Toxicogenomics of bromobenzene hepatotoxicity: a combined transcriptomics and proteomics approach. , 2003, Biochemical pharmacology.

[45]  Xin Chen,et al.  ADME-AP: a database of ADME associated proteins , 2002, Bioinform..

[46]  Angelika Görg,et al.  Two-dimensional electrophoresis , 1991 .

[47]  Sean Ekins,et al.  Generation and validation of rapid computational filters for cyp2d6 and cyp3a4. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[48]  Ronald T. Borchardt,et al.  Pharmaceutical profiling in drug discovery for lead selection , 2004 .

[49]  R. Weinshilboum.  Inheritance and drug response. , 2003, The New England journal of medicine.

[50]  Sean Ekins,et al.  Integrating computer-based de novo drug design and multidimensional filtering for desirable drugs , 2002 .

[51]  Robert P Tonge,et al.  Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[52]  Tatiana Nikolskaya,et al.  Early prediction of drug metabolism and toxicity: systems biology approach and modeling. , 2004, Drug discovery today.

[53]  K. Kolaja,et al.  Acute molecular markers of rodent hepatic carcinogenesis identified by transcription profiling. , 2004, Chemical research in toxicology.

[54]  D. Kell,et al.  Metabolomics by numbers: acquiring and understanding global metabolite data. , 2004, Trends in biotechnology.

[55]  Sean Ekins,et al.  A NOVEL METHOD FOR VISUALIZING NUCLEAR HORMONE RECEPTOR NETWORKS RELEVANT TO DRUG METABOLISM , 2005, Drug Metabolism and Disposition.

[56]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[57]  Daniel Hanisch,et al.  Co-clustering of biological networks and gene expression data , 2002, ISMB.

[58]  Haidong Wang,et al.  Discovering molecular pathways from protein interaction and gene expression data , 2003, ISMB.

[59]  E. Hood.  Proteomics: characterizing the cogs in the machinery of life. , 2003, Environmental health perspectives.

[60]  Trey Ideker,et al.  Building with a scaffold: emerging strategies for high- to low-level cellular modeling. , 2003, Trends in biotechnology.

[61]  Silvio Albertini,et al.  Modulation of gene and protein expression by carbon tetrachloride in the rat liver. , 2002, Toxicology and applied pharmacology.

[62]  John C Lindon,et al.  Integrated application of transcriptomics and metabonomics yields new insight into the toxicity due to paracetamol in the mouse. , 2004, Journal of pharmaceutical and biomedical analysis.

[63]  R. Ulrich,et al.  Overview of an interlaboratory collaboration on evaluating the effects of model hepatotoxicants on hepatic gene expression. , 2004, Environmental health perspectives.

[64]  M. Rawlins.  Cutting the cost of drug development? , 2004, Nature Reviews Drug Discovery.

[65]  Chris Beecher,et al.  Metabolic profiling on the right path , 2000, Nature Biotechnology.

[66]  David E. Leahy,et al.  Drug discovery information integration: virtual humans for pharmacokinetics , 2004 .

[67]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[68]  R. Christopher,et al.  Data‐Driven Computer Simulation of Human Cancer Cell , 2004, Annals of the New York Academy of Sciences.

[69]  E. Werner.  In silico multicellular systems biology and minimal genomes. , 2003, Drug discovery today.